Xencor, Inc Interest Income (Expense), Net
Xencor, Inc (XNCR) reported Interest Income (Expense), Net of $31.93 million for the 12-month period ending 2024-12-31, per its 10-K filed 2025-02-27.
Financial Statements › Income Statement › Other Income
us-gaap:InterestIncomeExpenseNet · last filed 2025-02-27
- Xencor, Inc interest income (expense), net for the quarter ending 2024-03-31 was $7.47M, a 158.33% increase year-over-year.
- Xencor, Inc interest income (expense), net for the quarter ending 2023-12-31 was $7.66M, a 268.04% increase year-over-year.
- Xencor, Inc interest income (expense), net for the quarter ending 2023-09-30 was $5.02M, a 263.74% increase year-over-year.
- Xencor, Inc interest income (expense), net for the quarter ending 2023-06-30 was $3.76M, a 424.97% increase year-over-year.
- Xencor, Inc interest income (expense), net for fiscal 2024 was $31.93M, a 65.18% increase from fiscal 2023.
- Xencor, Inc interest income (expense), net for fiscal 2023 was $19.33M, a 300.23% increase from fiscal 2022.
- Xencor, Inc interest income (expense), net for fiscal 2022 was $4.83M, a 468.90% increase from fiscal 2021.
- Xencor, Inc interest income (expense), net for fiscal 2021 was $849.00K, a 88.31% decline from fiscal 2020.
| Period end | Interest Income (Expense), Net 3 month | Interest Income (Expense), Net 6 month | Interest Income (Expense), Net 9 month | Interest Income (Expense), Net 12 month | Interest Income (Expense), Net 12 month as first filed |
|---|---|---|---|---|---|
| 2024-12-31 | $31.93M 10-K · filed 2025-02-27 | ||||
| 2024-03-31 | $7.47M 10-Q · filed 2024-05-09 | $15.13M derived: sum of 2 quarters · filed 2025-02-27 | $20.15M derived: sum of 3 quarters · filed 2025-02-27 | $23.91M derived: sum of 4 quarters · filed 2025-02-27 | |
| 2023-12-31 | $7.66M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $12.68M derived: sum of 2 quarters · filed 2025-02-27 | $16.44M derived: sum of 3 quarters · filed 2025-02-27 | $19.33M 10-K · filed 2025-02-27 | $18.63M 10-K · filed 2024-02-29 |
| 2023-09-30 | $5.02M 10-Q · filed 2023-11-08 | $8.78M derived: sum of 2 quarters · filed 2023-11-08 | $11.67M 10-Q · filed 2023-11-08 | $13.75M derived: sum of 4 quarters · filed 2025-02-27 | |
| 2023-06-30 | $3.76M 10-Q · filed 2023-08-03 | $6.66M 10-Q · filed 2023-08-03 | $8.74M derived: sum of 3 quarters · filed 2025-02-27 | $10.12M derived: sum of 4 quarters · filed 2025-02-27 | |
| 2023-03-31 | $2.89M 10-Q · filed 2024-05-09 | $4.97M derived: sum of 2 quarters · filed 2025-02-27 | $6.35M derived: sum of 3 quarters · filed 2025-02-27 | $7.07M derived: sum of 4 quarters · filed 2025-02-27 | |
| 2022-12-31 | $2.08M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $3.46M derived: sum of 2 quarters · filed 2025-02-27 | $4.18M derived: sum of 3 quarters · filed 2025-02-27 | $4.83M 10-K · filed 2025-02-27 | $4.82M 10-K · filed 2023-02-27 |
| 2022-09-30 | $1.38M 10-Q · filed 2023-11-08 | $2.10M derived: sum of 2 quarters · filed 2023-11-08 | $2.75M 10-Q · filed 2023-11-08 | $3.04M derived: sum of 4 quarters · filed 2024-02-29 | |
| 2022-06-30 | $717.00K 10-Q · filed 2023-08-03 | $1.37M 10-Q · filed 2023-08-03 | $1.66M derived: sum of 3 quarters · filed 2024-02-29 | $1.86M derived: sum of 4 quarters · filed 2024-02-29 | |
| 2022-03-31 | $653.00K 10-Q · filed 2023-05-08 | $944.00K derived: sum of 2 quarters · filed 2024-02-29 | $1.14M derived: sum of 3 quarters · filed 2024-02-29 | $1.29M derived: sum of 4 quarters · filed 2024-02-29 | |
| 2021-12-31 | $291.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $487.00K derived: sum of 2 quarters · filed 2024-02-29 | $634.00K derived: sum of 3 quarters · filed 2024-02-29 | $849.00K 10-K · filed 2024-02-29 | |
| 2021-09-30 | $196.00K 10-Q · filed 2022-11-07 | $343.00K derived: sum of 2 quarters · filed 2022-11-07 | $558.00K 10-Q · filed 2022-11-07 | $1.27M derived: sum of 4 quarters · filed 2023-02-27 | |
| 2021-06-30 | $147.00K 10-Q · filed 2022-08-03 | $362.00K 10-Q · filed 2022-08-03 | $1.07M derived: sum of 3 quarters · filed 2023-02-27 | $2.50M derived: sum of 4 quarters · filed 2023-02-27 | |
| 2021-03-31 | $215.00K 10-Q · filed 2022-05-05 | $927.00K derived: sum of 2 quarters · filed 2023-02-27 | $2.35M derived: sum of 3 quarters · filed 2023-02-27 | $4.44M derived: sum of 4 quarters · filed 2023-02-27 | |
| 2020-12-31 | $712.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-27 | $2.13M derived: sum of 2 quarters · filed 2023-02-27 | $4.22M derived: sum of 3 quarters · filed 2023-02-27 | $7.26M 10-K · filed 2023-02-27 | |
| 2020-09-30 | $1.42M 10-Q · filed 2021-11-08 | $3.51M derived: sum of 2 quarters · filed 2021-11-08 | $6.55M 10-Q · filed 2021-11-08 | $9.97M derived: sum of 4 quarters · filed 2022-02-24 | |
| 2020-06-30 | $2.09M 10-Q · filed 2021-08-04 | $5.13M 10-Q · filed 2021-08-04 | $8.55M derived: sum of 3 quarters · filed 2022-02-24 | $12.25M derived: sum of 4 quarters · filed 2022-02-24 | |
| 2020-03-31 | $3.04M 10-Q · filed 2021-05-05 | $6.46M derived: sum of 2 quarters · filed 2022-02-24 | $10.16M derived: sum of 3 quarters · filed 2022-02-24 | $13.77M derived: sum of 4 quarters · filed 2022-02-24 | |
| 2019-12-31 | $3.42M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | $7.12M derived: sum of 2 quarters · filed 2022-02-24 | $10.73M derived: sum of 3 quarters · filed 2022-02-24 | $13.62M 10-K · filed 2022-02-24 | |
| 2019-09-30 | $3.70M 10-Q · filed 2020-11-06 | $7.31M derived: sum of 2 quarters · filed 2020-11-06 | $10.20M 10-Q · filed 2020-11-06 | $13.01M derived: sum of 4 quarters · filed 2021-02-24 | |
| 2019-06-30 | $3.62M 10-Q · filed 2020-08-05 | $6.50M 10-Q · filed 2020-08-05 | $9.31M derived: sum of 3 quarters · filed 2021-02-24 | $11.95M derived: sum of 4 quarters · filed 2021-02-24 | |
| 2019-03-31 | $2.89M 10-Q · filed 2020-05-08 | $5.69M derived: sum of 2 quarters · filed 2021-02-24 | $8.34M derived: sum of 3 quarters · filed 2021-02-24 | $10.82M derived: sum of 4 quarters · filed 2021-02-24 | |
| 2018-12-31 | $2.81M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-24 | $5.45M derived: sum of 2 quarters · filed 2021-02-24 | $7.93M derived: sum of 3 quarters · filed 2021-02-24 | $9.09M 10-K · filed 2021-02-24 | |
| 2018-09-30 | $2.64M 10-Q · filed 2019-11-05 | $5.13M derived: sum of 2 quarters · filed 2019-11-05 | $6.28M 10-Q · filed 2019-11-05 | $7.33M derived: sum of 4 quarters · filed 2020-02-25 | |
| 2018-06-30 | $2.48M 10-Q · filed 2019-08-07 | $3.64M 10-Q · filed 2019-08-07 | $4.68M derived: sum of 3 quarters · filed 2020-02-25 | $5.73M derived: sum of 4 quarters · filed 2020-02-25 | |
| 2018-03-31 | $1.15M 10-Q · filed 2019-05-09 | $2.20M derived: sum of 2 quarters · filed 2020-02-25 | $3.25M derived: sum of 3 quarters · filed 2020-02-25 | ||
| 2017-12-31 | $1.05M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-25 | $2.09M derived: sum of 2 quarters · filed 2020-02-25 | $4.18M 10-K · filed 2020-02-25 | ||
| 2017-09-30 | $1.04M 10-Q · filed 2018-11-05 | $3.13M 10-Q · filed 2018-11-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |